<?xml version="1.0" encoding="iso-8859-1" ?>
<rss version="2.0" xmlns:s="http://resources.bnet.com/">
<channel>
	<title><![CDATA[exclusivity Resources | BNET]]></title>
	<link><![CDATA[http://resources.bnet.com/topic/exclusivity.html]]></link>
	<description><![CDATA[White papers, case studies, business articles, and blog posts relating to exclusivity]]></description>
	<s:counts start="0" returned="20" found="51" />
	<language>en-us</language>
	<item>
		<title><![CDATA[Penwest Pharmaceuticals Q4 2008 Earnings Call Transcript]]></title>
		<link><![CDATA[http://www.bnet.com/2462-14055_23-275604.html]]></link>
		<description><![CDATA[ Question-and-Answer SessionOperator: Operator Instructions. Your first question comes from the line of Bert Hazlett. Your line is open. Robert Hazlett - BMO Capital Markets Thanks Jennifer. I have a couple of questions. First just on CFO and the timing. Is Frank slotted to move into that role or are...]]></description>
		<s:doctype><![CDATA[Earnings calls]]></s:doctype>
		<pubDate>Wed, 04 Mar 2009 11:29:11 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/patent.html"><![CDATA[Patent]]></category>
		<category domain="http://resources.bnet.com/topic/call+transcript.html"><![CDATA[Call Transcript]]></category>
		<category domain="http://resources.bnet.com/topic/earnings.html"><![CDATA[Earnings]]></category>
		<category domain="http://resources.bnet.com/topic/exclusivity.html"><![CDATA[Exclusivity]]></category>
		<category domain="http://resources.bnet.com/topic/penwest+pharmaceuticals+co..html"><![CDATA[Penwest Pharmaceuticals Co.]]></category>
		<category domain="http://resources.bnet.com/topic/litigation.html"><![CDATA[Litigation]]></category>
		<category domain="http://resources.bnet.com/topic/financial+services.html"><![CDATA[Financial Services]]></category>
		<category domain="http://resources.bnet.com/topic/investment.html"><![CDATA[Investment]]></category>
		<category domain="http://resources.bnet.com/topic/business+operations.html"><![CDATA[Business Operations]]></category>
		<category domain="http://resources.bnet.com/topic/finance.html"><![CDATA[Finance]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://resources.bnet.com/topic/seeking+alpha.html"><![CDATA[Seeking Alpha]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">PPCO</category>
		<category domain="tickers">PPCO</category>
	</item>
	<item>
		<title><![CDATA[Schering-Plough, Sepracor Sign Deal to End Clarinex Exclusivity in 2012]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/1000542/schering-plough-sepracor-sign-deal-to-end-clarinex-exclusivity-in-2012/]]></link>
		<description><![CDATA[Schering Plough and Sepracor have settled a patent dispute with Indian generics maker Dr. Reddy's over Clarinex. The settlement brings forward the end of patent exclusivity on Clarinex to 2012. Previously, the assumption had been that Schering's exclusivity with Clarinex would last until 2020.    The terms of...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Mon, 29 Dec 2008 16:35:55 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/schering-plough+corp..html"><![CDATA[Schering-Plough Corp.]]></category>
		<category domain="http://resources.bnet.com/topic/sepracor+inc..html"><![CDATA[Sepracor Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/exclusivity.html"><![CDATA[Exclusivity]]></category>
		<category domain="http://resources.bnet.com/topic/clarinex.html"><![CDATA[Clarinex]]></category>
		<category domain="http://resources.bnet.com/topic/schering.html"><![CDATA[Schering]]></category>
		<category domain="http://resources.bnet.com/topic/clarinex+patent.html"><![CDATA[Clarinex Patent]]></category>
		<category domain="http://resources.bnet.com/topic/litigation.html"><![CDATA[Litigation]]></category>
		<category domain="http://resources.bnet.com/topic/business+operations.html"><![CDATA[Business Operations]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">SGP</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">SEPR</category>
		<category domain="tickers">SGP,SEPR</category>
	</item>
	<item>
		<title><![CDATA[US FDA grants pediatric exclusivity for UCB&#39;s Keppra(R)]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_pwwi/is_200806/ai_n25497998]]></link>
		<description><![CDATA[* Period of exclusivity until January 2009 in the US   * Pediatric indication filed with FDA ]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Fri, 06 Jun 2008 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/exclusivity.html"><![CDATA[exclusivity]]></category>
		<category domain="http://resources.bnet.com/topic/fda.html"><![CDATA[FDA]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
	<item>
		<title><![CDATA[The significance of the local in immigration regulation.]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_hb6402/is_200802/ai_n25607529]]></link>
		<description><![CDATA[The proliferation of state and local regulation designed to control  immigrant movement generated considerable media attention and  high-profile lawsuits in 2006 and 2007. Proponents and opponents of  these measures share one basic assumption, with deep roots in  constitutional doctrine and political rhetoric: immigration control is ...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Fri, 01 Feb 2008 23:59:59 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/alien.html"><![CDATA[alien]]></category>
		<category domain="http://resources.bnet.com/topic/benefit.html"><![CDATA[benefit]]></category>
		<category domain="http://resources.bnet.com/topic/citizenship.html"><![CDATA[CITIZENSHIP]]></category>
		<category domain="http://resources.bnet.com/topic/council.html"><![CDATA[Council]]></category>
		<category domain="http://resources.bnet.com/topic/exclusivity.html"><![CDATA[exclusivity]]></category>
		<category domain="http://resources.bnet.com/topic/immigrant.html"><![CDATA[immigrant]]></category>
		<category domain="http://resources.bnet.com/topic/immigration.html"><![CDATA[Immigration]]></category>
		<category domain="http://resources.bnet.com/topic/immigration.html"><![CDATA[immigration]]></category>
		<category domain="http://resources.bnet.com/topic/locality.html"><![CDATA[locality]]></category>
		<category domain="http://resources.bnet.com/topic/park.html"><![CDATA[Park]]></category>
		<category domain="http://resources.bnet.com/topic/regulation.html"><![CDATA[regulation]]></category>
		<category domain="http://resources.bnet.com/topic/u.s..html"><![CDATA[U.S.]]></category>
		<category domain="http://resources.bnet.com/topic/u.s.+congress.html"><![CDATA[U.S. Congress]]></category>
		<category domain="http://resources.bnet.com/topic/valley.html"><![CDATA[Valley]]></category>
		<category domain="http://resources.bnet.com/topic/worker.html"><![CDATA[worker]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
	<item>
		<title><![CDATA[Territorial behavior.]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_hb5057/is_200704/ai_n19223128]]></link>
		<description><![CDATA[By Paul Sweeting       The European Union wants to know why downloads from iTunes cost the  equivalent of $1.32 in euro-zone territories but go for $1.56 per track  in the U.K. and $1.43 in Norway.       Anti-trust investigators...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Mon, 09 Apr 2007 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/apple+inc..html"><![CDATA[Apple Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/apple+itunes.html"><![CDATA[Apple iTunes]]></category>
		<category domain="http://resources.bnet.com/topic/digital-rights+management.html"><![CDATA[digital-rights management]]></category>
		<category domain="http://resources.bnet.com/topic/exclusivity.html"><![CDATA[exclusivity]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">AAPL</category>
		<category domain="tickers">AAPL</category>
	</item>
	<item>
		<title><![CDATA[Anheuser-Busch secured alcohol category exclusivity during NBC broadcasts of Super Bowl XLIII in 2009 and Super Bowl XLVI in 2012]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m3289/is_8_175/ai_n16690277]]></link>
		<description><![CDATA[Anheuser-Busch secured alcohol category exclusivity during NBC broadcasts of Super Bowl XLIII in 2009 and Super Bowl XLVI in 2012, securing the brewer a significant presence in all NFL broadcasts on the network through 2012.]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Tue, 01 Aug 2006 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/anheuser-busch.html"><![CDATA[Anheuser-Busch]]></category>
		<category domain="http://resources.bnet.com/topic/exclusivity.html"><![CDATA[exclusivity]]></category>
		<category domain="http://resources.bnet.com/topic/nbc+universal+inc..html"><![CDATA[NBC Universal Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">BUD</category>
		<category domain="tickers">BUD</category>
	</item>
	<item>
		<title><![CDATA[PFIZER INC - 1st Quarter Results.]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_hb5937/is_200604/ai_n23960346]]></link>
		<description><![CDATA[Pfizer First-Quarter 2006 Financial Results                     Reflect Operating and Financial Strength          ($ billions, except per-share amounts)      ...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Wed, 19 Apr 2006 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/company.html"><![CDATA[Company]]></category>
		<category domain="http://resources.bnet.com/topic/exclusivity.html"><![CDATA[exclusivity]]></category>
		<category domain="http://resources.bnet.com/topic/foreign-exchange.html"><![CDATA[foreign-exchange]]></category>
		<category domain="http://resources.bnet.com/topic/income.html"><![CDATA[income]]></category>
		<category domain="http://resources.bnet.com/topic/lipitor.html"><![CDATA[Lipitor]]></category>
		<category domain="http://resources.bnet.com/topic/pfizer+inc..html"><![CDATA[Pfizer Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/r%2526d.html"><![CDATA[R&D]]></category>
		<category domain="http://resources.bnet.com/topic/revenue.html"><![CDATA[revenue]]></category>
		<category domain="http://resources.bnet.com/topic/sales.html"><![CDATA[sales]]></category>
		<category domain="http://resources.bnet.com/topic/tax.html"><![CDATA[tax]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">PFE</category>
		<category domain="tickers">PFE</category>
	</item>
	<item>
		<title><![CDATA[Teva Announces FDA Determination That Generic Pravachol Exclusivity Has Not Been Triggered]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2006_April_12/ai_n26825886]]></link>
		<description><![CDATA[JERUSALEM -- Teva Pharmaceutical Industries Ltd. (Nasdaq:TEVA) announced today that further to its press release dated March 16, 2006, the U.S. Food and Drug Administration has denied Apotex's request for an agency determination that 180-day exclusivity for pravastatin 10, 20, and 40 mg has been triggered and run. Teva expects...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Wed, 12 Apr 2006 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/exclusivity.html"><![CDATA[exclusivity]]></category>
		<category domain="http://resources.bnet.com/topic/fda.html"><![CDATA[FDA]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
	<item>
		<title><![CDATA[Teva Provides Update on Generic Pravachol Exclusivity]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2006_March_16/ai_n26797924]]></link>
		<description><![CDATA[JERUSALEM -- Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that United States Court of Appeals for the District of Columbia has vacated the FDA's determination that Teva's exclusivity on pravastatin 10, 20, and 40 mg had been triggered and remanded the matter back to the FDA for further decision-making....]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Thu, 16 Mar 2006 00:00:00 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/exclusivity.html"><![CDATA[exclusivity]]></category>
		<category domain="http://resources.bnet.com/topic/fda.html"><![CDATA[FDA]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
	<item>
		<title><![CDATA[Boutique buildings now catering to the latest tastes of home buyers]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m3601/is_28_52/ai_n16101779]]></link>
		<description><![CDATA[More and more house hunters are thinking small and dropping their mortgage money on one of the growing number of luxury boutique apartment buildings sprouting in the city.  Typically 20-units of less, what these mini-masterpieces lack in size they more than make up for in the myriad of super...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Wed, 22 Feb 2006 23:59:59 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/amenity.html"><![CDATA[amenity]]></category>
		<category domain="http://resources.bnet.com/topic/exclusivity.html"><![CDATA[exclusivity]]></category>
		<category domain="http://resources.bnet.com/topic/marketing.html"><![CDATA[MARKETING]]></category>
		<category domain="http://resources.bnet.com/topic/prudential+insurance+company+of+america.html"><![CDATA[Prudential Insurance Company of America]]></category>
		<category domain="http://resources.bnet.com/topic/tenant.html"><![CDATA[tenant]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">PRU</category>
		<category domain="tickers">PRU</category>
	</item>
	<item>
		<title><![CDATA[Bioenvision to Present at the 24th Annual JPMorgan Healthcare Conference]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2006_Jan_5/ai_n26717001]]></link>
		<description><![CDATA[NEW YORK -- Bioenvision, Inc. (Nasdaq: BIVN) announced today that Dr. Christopher B. Wood, Chairman and Chief Executive Officer of the Company, will present at the 24th Annual JPMorgan Healthcare Conference, Tuesday, January 10, 2006, at 11:30 am PST in San Francisco. An audio webcast of the presentation will be...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Thu, 05 Jan 2006 23:59:59 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/compound.html"><![CDATA[compound]]></category>
		<category domain="http://resources.bnet.com/topic/exclusivity.html"><![CDATA[exclusivity]]></category>
		<category domain="http://resources.bnet.com/topic/genzyme+corp..html"><![CDATA[Genzyme Corp.]]></category>
		<category domain="http://resources.bnet.com/topic/government.html"><![CDATA[Government]]></category>
		<category domain="http://resources.bnet.com/topic/j.p.+morgan+chase+%2526+co..html"><![CDATA[J.P. Morgan Chase & Co.]]></category>
		<category domain="http://resources.bnet.com/topic/marketing.html"><![CDATA[MARKETING]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">GENZ</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">JPM</category>
		<category domain="tickers">GENZ,JPM</category>
	</item>
	<item>
		<title><![CDATA[INTERNET PROTOCOL AND BROADBAND SERVICES]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_hb5665/is_200511/ai_n23702398]]></link>
		<description><![CDATA[Statement of K. James Yager Chief Executive Officer, Barrington Broadcasting Company, LLC Committee on House Energy and Commerce Subcommittee on Telecommunications and the Internet November 09, 2005 Thank you, Mr. Chairman, for the opportunity to appear before the Subcommittee on Telecommunications and the Internet today. I am James Yager, Chief...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Thu, 10 Nov 2005 23:59:59 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/broadband.html"><![CDATA[broadband]]></category>
		<category domain="http://resources.bnet.com/topic/broadcaster.html"><![CDATA[broadcaster]]></category>
		<category domain="http://resources.bnet.com/topic/broadcasting.html"><![CDATA[broadcasting]]></category>
		<category domain="http://resources.bnet.com/topic/cable.html"><![CDATA[Cable]]></category>
		<category domain="http://resources.bnet.com/topic/exclusivity.html"><![CDATA[exclusivity]]></category>
		<category domain="http://resources.bnet.com/topic/fcc.html"><![CDATA[FCC]]></category>
		<category domain="http://resources.bnet.com/topic/government.html"><![CDATA[Government]]></category>
		<category domain="http://resources.bnet.com/topic/ip.html"><![CDATA[IP]]></category>
		<category domain="http://resources.bnet.com/topic/marketing.html"><![CDATA[MARKETING]]></category>
		<category domain="http://resources.bnet.com/topic/networking.html"><![CDATA[NETWORKING]]></category>
		<category domain="http://resources.bnet.com/topic/programming.html"><![CDATA[programming]]></category>
		<category domain="http://resources.bnet.com/topic/telecommunications.html"><![CDATA[TELECOMMUNICATIONS]]></category>
		<category domain="http://resources.bnet.com/topic/tv.html"><![CDATA[TV]]></category>
		<category domain="http://resources.bnet.com/topic/u.s.+congress.html"><![CDATA[U.S. Congress]]></category>
		<category domain="http://resources.bnet.com/topic/video.html"><![CDATA[video]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
	<item>
		<title><![CDATA[Furious George]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_kmlea/is_200509/ai_n15348927]]></link>
		<description><![CDATA[IN 1989, ASSISTANT ATTORNEY GENERAL WILLIAM BARR issued an extraordinary, and evidently unsolicited, legal opinion to all agencies of the federal government. Barr headed the prestigious Office of Legal Counsel, which advises the president and executive branch on constitutional issues, and his memo read like a Top Ten list of...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Thu, 01 Sep 2005 23:59:59 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/exclusivity.html"><![CDATA[exclusivity]]></category>
		<category domain="http://resources.bnet.com/topic/government.html"><![CDATA[Government]]></category>
		<category domain="http://resources.bnet.com/topic/president.html"><![CDATA[president]]></category>
		<category domain="http://resources.bnet.com/topic/software.html"><![CDATA[SOFTWARE]]></category>
		<category domain="http://resources.bnet.com/topic/u.s.+congress.html"><![CDATA[U.S. Congress]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
	<item>
		<title><![CDATA[ESPN reaps ratings for 2 NFL games]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_kmusa/is_200409/ai_n6881866]]></link>
		<description><![CDATA[In the latest sports spinoff from a Florida hurricane, some viewers could have watched two NFL games Sunday night -- and the same ads on two networks.  CBS planned to show the Pittsburgh Steelers at Miami Dolphins game at 1 p.m. ET Sunday to 15% of the USA. But...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Mon, 27 Sep 2004 23:59:59 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/cbs+corp..html"><![CDATA[CBS Corp.]]></category>
		<category domain="http://resources.bnet.com/topic/espn.html"><![CDATA[ESPN]]></category>
		<category domain="http://resources.bnet.com/topic/exclusivity.html"><![CDATA[exclusivity]]></category>
		<category domain="http://resources.bnet.com/topic/games.html"><![CDATA[Games]]></category>
		<category domain="http://resources.bnet.com/topic/nfl.html"><![CDATA[NFL]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">CBS</category>
		<category domain="tickers">CBS</category>
	</item>
	<item>
		<title><![CDATA[Research and Markets: Intellectual Property Strategies for Pharmaceutical Development]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2004_July_14/ai_n6105754]]></link>
		<description><![CDATA[DUBLIN, Ireland -- According to Tufts University in 2003, a new chemical entity NCE costs on average US$897 million to develop, including cost of post-approval research (rising from US$803 M in 2001)  Research and Markets (http://www.researchandmarkets.com) has announced the addition of Intellectual Property Strategies for Pharmaceutical Development to their...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Wed, 14 Jul 2004 23:59:59 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/exclusivity.html"><![CDATA[exclusivity]]></category>
		<category domain="http://resources.bnet.com/topic/patent.html"><![CDATA[patent]]></category>
		<category domain="http://resources.bnet.com/topic/tufts+university.html"><![CDATA[Tufts University]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
	<item>
		<title><![CDATA[IMPAX Granted FDA 180-Day Exclusivity for Metformin HCl Extended Release Tablets, 500mg; Selectively Waived to TEVA Pharmaceuticals USA Inc]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2004_June_18/ai_n6084235]]></link>
		<description><![CDATA[HAYWARD, Calif. -- IMPAX Laboratories, Inc. (Nasdaq:IPXL) announced that the U.S. Food and Drug Administration FDA has granted IMPAX a second tier 180-day exclusivity related to its pending ANDA for a generic version of Glucophage XRR, Metformin HCl Extended Release Tablets, 500mg. Impax has selectively waived its rights to this...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Fri, 18 Jun 2004 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/exclusivity.html"><![CDATA[exclusivity]]></category>
		<category domain="http://resources.bnet.com/topic/fda.html"><![CDATA[FDA]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
	<item>
		<title><![CDATA[In Short Supply]]></title>
		<link><![CDATA[http://jobfunctions.bnet.com/abstract.aspx?docid=242618]]></link>
		<description><![CDATA[Just as scarcity ignites passion in collectors, exclusivity fans the flame for a wide range of consumers. Building that special aura around one's own products or services requires deft handling of a carefully crafted marketing program. The challenge is to successfully walk the line between enticing customers and raising barriers...]]></description>
		<s:doctype><![CDATA[White papers]]></s:doctype>
		<pubDate>Tue, 01 Jun 2004 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/scarcity.html"><![CDATA[Scarcity]]></category>
		<category domain="http://resources.bnet.com/topic/entrepreneur.com+inc..html"><![CDATA[Entrepreneur.com Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/exclusivity.html"><![CDATA[Exclusivity]]></category>
		<category domain="http://resources.bnet.com/topic/entrepreneurship.html"><![CDATA[Entrepreneurship]]></category>
		<category domain="http://resources.bnet.com/topic/management.html"><![CDATA[Management]]></category>
	</item>
	<item>
		<title><![CDATA[Lab companies crowd generic drug market]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_qn4176/is_20040324/ai_n14570887]]></link>
		<description><![CDATA[HAYWARD -- Impax Laboratories launched its generic version of a major antidepression drug Monday, but the bad news for the company is that competitor Eon Labs is now launching its version six months earlier than expected.    The market for the generic version of GlaxoSmithKline's Wellbutrin SR 150mg...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Wed, 24 Mar 2004 23:59:59 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/banc+of+america+securities.html"><![CDATA[Banc of America Securities]]></category>
		<category domain="http://resources.bnet.com/topic/benefits.html"><![CDATA[Benefits]]></category>
		<category domain="http://resources.bnet.com/topic/exclusivity.html"><![CDATA[exclusivity]]></category>
		<category domain="http://resources.bnet.com/topic/glaxosmithkline+plc..html"><![CDATA[GlaxoSmithKline Plc.]]></category>
		<category domain="http://resources.bnet.com/topic/government.html"><![CDATA[Government]]></category>
		<category domain="http://resources.bnet.com/topic/sales.html"><![CDATA[SALES]]></category>
		<category domain="http://resources.bnet.com/topic/teva.html"><![CDATA[Teva]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">GSK</category>
		<category domain="tickers">GSK</category>
	</item>
	<item>
		<title><![CDATA[Special edition has power]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_6783/is_2004_March_19/ai_n28184926]]></link>
		<description><![CDATA[Just 400 right-hand drive Vauxhall Monaros are destined for the UK this year, giving it the same sort of exclusivity as the Nissan and Chrysler's rival Crossfire coupe from America.  However, while the similarly-priced Crossfire offers just 266bhp, and pale performance by comparison, the Vauxhall aims to sell on...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Fri, 19 Mar 2004 23:59:59 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/america.html"><![CDATA[America]]></category>
		<category domain="http://resources.bnet.com/topic/car.html"><![CDATA[car]]></category>
		<category domain="http://resources.bnet.com/topic/chrysler+llc.html"><![CDATA[Chrysler LLC]]></category>
		<category domain="http://resources.bnet.com/topic/exclusivity.html"><![CDATA[exclusivity]]></category>
		<category domain="http://resources.bnet.com/topic/nissan+motor+co.+ltd..html"><![CDATA[Nissan Motor Co. Ltd.]]></category>
		<category domain="http://resources.bnet.com/topic/u.k..html"><![CDATA[U.K.]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">NSANY</category>
		<category domain="tickers">NSANY</category>
	</item>
	<item>
		<title><![CDATA[Luxury Pricing]]></title>
		<link><![CDATA[http://jobfunctions.bnet.com/abstract.aspx?docid=162569]]></link>
		<description><![CDATA[Although the luxury goods market is renowned for commanding lucrative margins, there are valid reasons for this. The innovation processes, the creativity, and long development stages some items go through has to bring a return on the initial investment to allow the creative process to continue. In order to create...]]></description>
		<s:doctype><![CDATA[White papers]]></s:doctype>
		<pubDate>Tue, 01 Oct 2002 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/interbrand.html"><![CDATA[Interbrand]]></category>
		<category domain="http://resources.bnet.com/topic/pricing+strategy.html"><![CDATA[Pricing Strategy]]></category>
		<category domain="http://resources.bnet.com/topic/exclusivity.html"><![CDATA[Exclusivity]]></category>
		<category domain="http://resources.bnet.com/topic/retail.html"><![CDATA[Retail]]></category>
		<category domain="http://resources.bnet.com/topic/pricing.html"><![CDATA[Pricing]]></category>
		<category domain="http://resources.bnet.com/topic/leadership.html"><![CDATA[Leadership]]></category>
		<category domain="http://resources.bnet.com/topic/strategy.html"><![CDATA[Strategy]]></category>
		<category domain="http://resources.bnet.com/topic/marketing+research.html"><![CDATA[Marketing Research]]></category>
		<category domain="http://resources.bnet.com/topic/marketing.html"><![CDATA[Marketing]]></category>
		<category domain="http://resources.bnet.com/topic/management.html"><![CDATA[Management]]></category>
	</item>
</channel>
</rss>
